Now showing items 5-7 of 7

    • Outcome after reduced chemotherapy for intermediate-risk neuroblastoma 

      Baker, David L.; Schmidt, Mary L.; Cohn, Susan L.; Maris, John M.; London, Wendy B.; Buxton, Allen; Stram, Daniel; Castleberry, Robert P.; Shimada, Hiroyuki; Sandler, Anthony; Shamberger, Robert C.; Look, Thomas; Reynolds, Patrick; Seeger, Robert C.; Matthay, Katherine (Massachusetts Medical Society, 2010-09-30)
      Background The survival rate among patients with intermediate-risk neuroblastoma who receivedose-intensive chemotherapy is excellent, but the survival rate among patients whoreceive reduced doses of chemotherapy for shorter ...
    • Pharmacogenomics of chemotherapeutic susceptibility and toxicity 

      Zhang, Wei; Moen, Erika L.; Godley, Lucy A.; Dolan, M. Eileen (BioMed Central, 2012-11)
      ABSTRACT: The goal of personalized medicine is to tailor a patient's treatment strategy on the basis of his or her unique genetic make-up. The field of oncology is beginning to incorporate many of the strategies of ...
    • Targeting the HGF-cMET Axis in Hepatocellular Carcinoma 

      Venepalli, Neeta K.; Goff, Laura (Hindawi Publishing Corporation, 2013-03)
      Under normal physiological conditions, the hepatocyte growth factor (HGF) and its receptor, the MET transmembrane tyrosine kinase (cMET), are involved in embryogenesis, morphogenesis, and wound healing. The HGF-cMET axis ...